Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: Sigmund who wrote (1058)	1/10/1998 11:19:00 PM
From: george	Respond to of 1894

Sigmund, The Pap smear has many different cells in various shapes and sizes. I just think that a computer is still too DUMB to make a correct decision more times than a human....in the case of the K-B observation, my understanding is that the computer measures an area of the slide and a computer can measure an area better than a human, I think....these are my reasons, for better or worse....maybe the FDA will say Yes on Neopath, but even if automated screening is better, I do not think that the FDA will stick out its neck for a good long time. I still LOVE my computer but do not expect it to do more than it is capable of doing. For the above reasons I own Accumed and have not been persuaded to buy Neopath (no insult intended to Neopath stockholders, as I would be the first to say I could be wrong.) George

To: Sigmund who wrote (1058)	1/11/1998 1:02:00 AM
From: Frank Buck	Read Replies (1) \| Respond to of 1894

Sigmund and Others, Just out of curiousity, I was wondering what you "thought" of the rumor regarding the NeoPath purchase of CYTC? (It was mentioned/posted in reply #1048...) Assuming Monday morning were to find a news statement confirming the rumor, would you Sigmund be, thrilled or chilled as a NeoPath shareholder? Sometimes there is a large move in the acquired stock price with an associated falling share price of the acquirer. I am not saying that would or should be the case here. It would however appear to make for one heck of a synergy and resulting company. Obviously if CYTC wanted to thwart the attempt (assuming it was an unsolicted-offer), they could always go on a buying-spree and saddle themselves with more-debt to maintain their autonomy. Maybe even pick up a company like AccuMed to accomplish that end. A little Deus-ex-machina (divine intervention). How would any AccuMed shareholder feel about that? Would any ACMI stockholder feel that it would enhance shareholder value in the long-run to be acquired? Once in a while the acquirer becomes the acquired. Wouldn't that be interesting. Obviously AccuMed doesn't appear to be in a position to acquire anyone at this point. AccuMed has made some rather strategic purchases of late, ie., ESP, Oncometrics. Obviously all this nonsense is just rumor, but the possibility does exist that there will be some type of consolidation in this sector. I believe Peter Gombrich or Len Prange of AccuMed alluded to this consolidation at some recent point. I for one think it would be premature at this stage, but...anything could happen-and usually does, when one least expects it. It seems like NeoPath is moving on something, perhaps this is it. It would seem more timely (before anyone would start throwing their stock or cash around for another company) to wait until after some of the litigation were to play out. Just thought it would be interesting to here what the general sentiment and comments would be. Dana, I know you aren't gonna touch this with a 10' pole - your excused. Frank